Catalogue

Weight & Metabolic

Incretin mimetics like semaglutide, tirzepatide and retatrutide, alongside mitochondrial and enzyme-targeting compounds. In research these are studied for how the body regulates appetite, handles glucose and spends energy — clinical trials of the incretin agonists have reported substantial reductions in body weight and improvements in metabolic markers. The throughline is signalling the body's own satiety and fuel-use pathways rather than overriding them.

Supplied for research use only. Not medicines, not evaluated by the European Medicines Agency, and not for human or veterinary consumption.